

Pending Claims:

The Pending Claims are set forth below:

1. (previously amended) An immortalized sebocyte derived from a human.
2. (previously amended) The sebocyte according to claim 1, characterized in that it is derived from a human sebaceous gland cell.
3. (previously amended) The sebocyte according to claim 2, characterized in that the sebaceous gland cell is a facial sebaceous gland cell.
4. (previously amended) The sebocyte according to claim 1, characterized in that it is present in form of a cell line.
5. (previously amended) The sebocyte according to claim 1, characterized in that it is immortalized by transfection of DNA.
6. (previously amended) The sebocyte according to claim 1, characterized in that it expresses a SV-40 large T antigen.
7. (previously amended) The sebocyte according to claim 1, characterized in that it exhibits features of a normal, non-transfected and differentiating sebocyte.
8. (previously amended) The sebocyte according to claim 1, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.
9. (previously amended) The sebocyte according to claim 1, characterized in that it is cloned.

10. Human sebocyte cell line DSM ACC2383.

11-22. (previously cancelled)

23. (previously added) The sebocyte according to claim 2, characterized in that it is present in form of a cell line.

24. (previously added) The sebocyte according to claim 2, characterized in that it is immortalized by transfection of DNA.

25. (previously added) The sebocyte according to claim 2, characterized in that it expresses a SV-40 large T antigen.

26. (previously added) The sebocyte according to claim 2, characterized in that it exhibits a feature of a normal, non-transfected and differentiating sebocyte.

27. (previously added) The sebocyte according to claim 2, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

28. (previously added) The sebocyte according to claim 2, characterized in that it is cloned.

29. (previously added) The sebocyte according to claim 3, characterized in that it is present in form of a cell line.

30. (previously added) The sebocyte according to claim 3, characterized in that it is immortalized by transfection of DNA.

31. (previously added) The sebocyte according to claim 3, characterized in that it expresses a SV-40 large T antigen.

32. (previously added) The sebocyte according to claim 3, characterized in that it exhibits a feature of a normal, non-transfected and differentiating sebocyte.

33. (previously added) The sebocyte according to claim 3, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

34. (previously added) The sebocyte according to claim 3, characterized in that it is cloned.

35. (previously added) The sebocyte according to claim 4, characterized in that it is immortalized by transfection of DNA.

36. (previously added) The sebocyte according to claim 4, characterized in that it expresses a SV-40 large T antigen.

37. (previously added) The sebocyte according to claim 4, characterized in that it exhibits a feature of a normal, non-transfected and differentiating sebocyte.

38. (previously added) The sebocyte according to claim 4, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

39. (previously withdrawn)

40. (previously added) The sebocyte according to claim 5, characterized in that it expresses a SV-40 large T antigen.

41. (previously added) The sebocyte according to claim 5, characterized in that it exhibits a feature of a normal, non-transfected and differentiating sebocyte.

42. (previously added) The sebocyte according to claim 5, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

43. (previously withdrawn)

44. (previously added) The sebocyte according to claim 6, characterized in that it exhibits a feature of a normal, non-transfected and differentiating sebocyte.

45. (previously added) The sebocyte according to claim 6, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

46. (previously withdrawn)

47. (previously added) The sebocyte according to claim 7, characterized in that its proliferation is modifiable by an androgen and/or retinoid.

48-62. (previously withdrawn)

63. (previously added) An immortalized sebocyte, wherein the sebocyte expresses one or more antigens selected from the group consisting of: sebaceous gland antigen, human milk fat globulin-1, human milk fat globulin-2, human epithelial sialomucin, Thomsen-Friedenreich antigen, mucin-type carcinoma-associated antigen, epithelial membrane antigen, Keratin 7, Keratin 13, Keratin 19, and 5 α -reductase of type 1.

64. (previously added) The sebocyte of claim 63, wherein the sebocyte expresses sebaceous gland antigen, human milk fat globulin-1, human milk fat globulin-2, human epithelial sialomucin, Thomsen-Friedenreich antigen, mucin-type carcinoma-associated antigen, epithelial membrane antigen, Keratin 7, Keratin 13, Keratin 19, and 5 α -reductase of type 1.

65. (previously added) The sebocyte of claim 63, wherein the sebocyte is in the form of a cell line.

66. (previously added) An immortalized sebocyte, wherein the sebocyte expresses one or more lipids selected from the group consisting of: squalene, wax ester, triglycerides, cholesterol, cholesterol ester, diglycerides, lanosterol, and free fatty acids.

67. (previously added) The sebocyte of claim 66, wherein the sebocyte expresses squalene, wax ester, triglycerides, cholesterol, cholesterol ester, diglycerides, lanosterol, and free fatty acids.

68. (previously added) The sebocyte of claim 66, wherein the sebocyte is in the form of a cell line.